Pluristem uses the preclinical hype gambit to whip up a quickie stock gain
The view from Endpoints
In the world of drug development, mouse data is a little like a broken twig on a confusing trail. Itmight tell you you’ve started down the right path and it might lead absolutely nowhere. In the vastmajority of cases, you wind up in the wilderness — completely lost and with nothing to show foryour effort.
Unless you put out the right kind of press release heralding your broken twig as a clear sign of major progress. And if you’re a public company, you can also get an instantaneous boost in your ailing stock price.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
